Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Respiri Limited ( (AU:RSH) ).
Respiri Limited reported significant growth in patient program enrolment, revenue, and cost savings for the December 2024 quarter, following its acquisition of Orb Health. The company experienced a 67% increase in patient programs and a 29% rise in revenue, while realizing annual cost savings of A$1.67M. The acquisition has expanded Respiri’s service offerings and is expected to contribute to profitability by 2025. The company plans to capitalize on growth opportunities through new contracts and leveraging CMS’s focus on accountable care relationships, with potential revenue upside from the integration of remote patient monitoring services.
More about Respiri Limited
Respiri Limited is an eHealth company that supports respiratory healthcare and Connected Care Management, primarily operating in the USA. The company focuses on patient programs that include Remote Patient Monitoring (RPM) and Chronic Care Management (CCM), collaborating with healthcare organizations to provide value-based healthcare solutions.
YTD Price Performance: 4.00%
Average Trading Volume: 253,500
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $69M
For a thorough assessment of RSH stock, go to TipRanks’ Stock Analysis page.
